Glycosuria is the presence of glucose in the urine, detected via dipstick (semiquantitative) or quantitative urine glucose testing. Normally, nearly all filtered glucose is reabsorbed by the proximal renal tubule (via SGLT2/SGLT1 transporters), so urine glucose is undetectable; glycosuria occurs when the plasma glucose exceeds the renal threshold (typically ~180 mg/dL, causing βoverflow glycosuria,β most commonly from uncontrolled diabetes mellitus) or when tubular reabsorption is impaired despite normal blood glucose (βrenal glycosuria,β a benign, often hereditary condition, or one seen with SGLT2-inhibitor therapy, Fanconi syndrome, or pregnancy). It is distinguished from glucosuria of pregnancy, a transient, benign finding caused by increased glomerular filtration rate (GFR) and reduced tubular reabsorption capacity during gestation, and from ketonuria, which reflects fat metabolism rather than carbohydrate spillover. Persistent glycosuria with normal serum glucose warrants evaluation for primary renal glycosuria or proximal tubulopathy rather than diabetes.
Historical note: physicians historically diagnosed diabetes (βdiabetes mellitus,β literally βsweet-tasting siphonβ) by the sweet taste of urine β the clinical ancestor of the modern glucose dipstick.
Other specified disorders of carbohydrate metabolism (includes primary/renal glycosuria)
NOTE
Note: When glycosuria is a documented manifestation of diabetes mellitus, do not code R81 separately β code only the appropriate diabetes category (E08-E13) per ICD-10-CM guidelines, since glycosuria is an inherent/integral finding of uncontrolled diabetes.
β οΈ Coding Note:R81 is used only when glycosuria is an isolated, unexplained finding β e.g., an incidental dipstick result pending workup β and should not be assigned when the underlying diabetic etiology is already documented, in which case the diabetes code alone captures the clinical picture per ICD-10-CM Chapter 4 guidelines. If the note documents βrenal glycosuriaβ or a tubular reabsorption defect without hyperglycemia, use E74.8 instead of R81. Watch for SGLT2-inhibitor therapy noted in the medication list β glycosuria in that context is an expected drug effect, not usually reportable as a separate diagnosis unless the provider flags it as clinically significant (e.g., recurrent UTI risk).